article · Tanzania journal of health research/Tanzania Journal of Health Research
This study investigated the role of CT scans in detecting abdominopelvic metastasis and its association with hormonal receptor status and staging in breast cancer patients at Ocean Road Cancer Institute. A cross-sectional study of 140 patients found that most were over 40 years old, with a mean age of 53.71 years. Over half (52.9%) had abdominopelvic metastasis, predominantly in the liver (47.9%). A significant majority (81%) presented with advanced stage 4 disease and were often hormone receptor-negative. Positive oestrogen receptor, positive progesterone receptor, and triple-negative breast cancer status were significantly associated with abdominopelvic metastases. The findings suggest a high disease burden and challenges in treatment selection, underscoring the importance of comprehensive tumour profiling.
This research helps understand how breast cancer spreads to the abdomen and pelvis, especially in advanced cases. Recognising the link between metastasis and hormonal status can improve diagnosis and guide more effective, personalised treatment strategies for patients, potentially leading to better outcomes and better management of the disease.
The abstract highlights the importance of comprehensive tumour profiling and CT scans for detecting abdominopelvic metastasis and understanding its association with hormonal receptor status. This information is valuable for clinicians in guiding treatment decisions and for diagnostic imaging companies developing advanced CT analysis tools. The research provides foundational insights for improving diagnostic protocols and personalised medicine approaches, suggesting it is early-stage research informing clinical practice.
AI-generated from the published abstract. Always read the original work before citing.
Background: Breast cancer is among the most common cancers in women globally. Most Tanzanian women diagnosed with breast cancer are at an advanced stage. This study aimed to examine the role of CT scan in detecting Abdominopelvic metastasis and its association with hormonal receptor status & staging among women with breast cancer. Methodology: A descriptive cross-sectional study was conducted at ORCI from July 2020 to December 2022, enrolling 140 patients with breast cancer. Abdominopelvic CT findings, staging, and hormone status data were recorded. A checklist developed by the Principal Investigator (PI) was used. The PI and a senior Radiologist read CT images. Data analysis was performed using SPSS Version 25. Multiple logistic regression was used to examine the factors associated with metastases. Statistical significance was set at a p-value of less than 0.05 Results: Majority (92%) of patients with breast cancer were > 40 years old, with a mean age of 53.71±11 years. Approximately 52.9% had abdominopelvic metastasis, and the liver was the most common (47.9%) site involved. Most of the patients (81%) had advanced-stage 4 and were hormonal receptor-negative. Positive Estrogen Receptor (ER) (AOR: 5.23, 95% CI: 2.32-11.76, p < 0.001, positive Progesterone Receptor (PR) (AOR: 0.64, 95% CI: 0.55-0.74, p < 0.001) and Triple Negative Breast Cancer (TNBC) (AOR: 1.28, 95% CI: 1.15-1.42, p < 0.001) were significantly associated with abdominopelvic metastases. Conclusion: The Majority of metastases were characterised by hypodense lesions and a non-enhancing pattern. The most common location of metastasis is the liver. A predominance of advanced-stage tumours and a significant proportion of cases with triple-negative hormonal receptor statuses suggest a high disease burden and challenges in treatment selection. The findings underscore the importance of comprehensive tumor profiling in guiding treatment decisions.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.4314/thrb.v26i5.21s
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
